Standard BioTools Inc. (NASDAQ:LAB - Get Free Report)'s stock price gapped up prior to trading on Friday . The stock had previously closed at $1.71, but opened at $1.82. Standard BioTools shares last traded at $1.82, with a volume of 88,225 shares changing hands.
Analyst Ratings Changes
Separately, TD Cowen cut their price target on shares of Standard BioTools from $2.75 to $2.50 and set a "buy" rating on the stock in a report on Thursday, October 31st.
Read Our Latest Analysis on Standard BioTools
Standard BioTools Stock Up 1.1 %
The firm has a market cap of $684.96 million, a P/E ratio of -2.59 and a beta of 1.57. The firm's fifty day moving average is $1.85 and its two-hundred day moving average is $2.00.
Institutional Trading of Standard BioTools
Hedge funds have recently modified their holdings of the business. Wolverine Trading LLC bought a new stake in shares of Standard BioTools during the 3rd quarter valued at $27,000. Xponance Inc. bought a new stake in shares of Standard BioTools during the 2nd quarter valued at $34,000. Nisa Investment Advisors LLC boosted its holdings in shares of Standard BioTools by 433.8% during the 3rd quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company's stock valued at $35,000 after buying an additional 14,732 shares in the last quarter. IQ EQ FUND MANAGEMENT IRELAND Ltd purchased a new position in shares of Standard BioTools in the 2nd quarter worth about $39,000. Finally, Creative Planning purchased a new position in shares of Standard BioTools in the 3rd quarter worth about $39,000. Institutional investors own 53.74% of the company's stock.
Standard BioTools Company Profile
(
Get Free Report)
Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.
Further Reading
Before you consider Standard BioTools, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Standard BioTools wasn't on the list.
While Standard BioTools currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
MarketBeat has just released its list of 20 stocks that Wall Street analysts hate. These companies may appear to have good fundamentals, but top analysts smell something seriously rotten. Are any of these companies lurking around your portfolio? Find out by clicking the link below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
